Drugs / scAAV1.tMCK.NTF3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03520751 | Apr 2027 → Apr 2029 expected | Charcot-Marie-Tooth disease type 1A | Nationwide Children's Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | scAAV1.tMCK.NTF3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03520751 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “recombinant AAV1 carrying a human NFT3 gene” NCT03520751 ↗ |
| Route | Intramuscular | “administered by intramuscular injections” NCT03520751 ↗ |